Abstract
For the sake of providing evidences that contribute to policy making or strategy planning in pharmaceutical industry, we tried to create new R&D indicators to foresight the picture of pharmaceutical industries. We found that R&D pipelines can be good drug-R&D-indicator. We also show new drug-patent-indicators for identifying patents related with pharmaceutical entities’ R&D progress (”Pre-clinical” → ”Phase 1” → ”Phase 2” → ”Phase 3”→ ”Filed ”→ ”Approved” → ”Marketed”). IPC Count, forward citations, and Citations to Non-Patent Literature are found as new drug-patent-indicators. Not only R&D pipelines but also patents extracted by new drug-patent-indicators are considered to foresight pharmaceutical industries’ potential of creating new drugs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
OECD Pharmaceutical Pricing Policies in a Global Market 216 (2008)
Mihara, K.: Considerations on patent valuation based on patent classification and citation in biotechnological field. Johokanri 54(11), 738–749 (2012)
OECD “Working Party on Industry Analysis Measuring patent ‘quality’: refined indicators for cross-country evidence” (2012) DSTI/EAS/IND/WPIA(2012)6
Goto, A., Genba, K., Suzuki, J., Tamada, S.: RIETEI Discussion Paper Series 6-J-018 (2006) (in Japanese)
Caviggioli, F., Schellato, G., Ughetto, E.: Understanding patent quality: evidence from patent opposition cases at the European Patent Office, http://www.epip.eu/conferences/epip06/papers/Parallel%20Session%20Papers/CAVIGGIOLI%20Federico.pdf#search='Understanding+patent+quality%3A+evidence+from+patent+opposition+cases+at+the+European+Patent+Office' (accessed October 25, 2011)
Trajtenbert, M.: A Penny for Your Quotes: Patent Citations and the Value of Innovation. RAND Journal of Economics 21(1), 172–187 (1990)
Narin, F., Hamilton, K.S., Olivastro, D.: The increasing linkage between U.S. technology and public science. Research Policy 26, 317–330 (1997)
Callaert, J., Van Looy, B., Verbeek, A., Debackere, K., Thijs, B.: Traces of Prior Art: An Analysis of Non-patent References found in Patent Documents. Scientometrics 69(1), 3–20 (2006)
Cassiman, B., Vaugelers, R., Zuniga, P.: In search of performance effects of (in)direct industry science links. Industrial and Corporate Change 17(4), 611–646 (2008)
Branstetter, L.: Exploring the Link Between Academic Science and Industrial Innovation. Annals of Economic and Statistics 79/80, 119–142 (2005)
OECD: Science, Technology and Industry Scoreboard, 1–275 (2013)
Osabe, Y., Jibu, M.: Development of new indicators for the launch of a Japanese version of NIH (1). Johokanri 56(7), 448–458 (2013) (in Japanese)
Osabe, Y., Jibu, M.: Development of new indicators for the launch of a Japanese version of NIH (2). Johokanri 56(9) (2013) (in press & in Japanese)
Osabe, Y., Jibu, M.: Development of new indicators for the launch of a Japanese version of NIH (3). Johokanri 56(10) (2014) (in press & in Japanese)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Jibu, M., Osabe, Y. (2014). Refined R&D Indicators for Pharmaceutical Industry. In: Park, J., Pan, Y., Kim, CS., Yang, Y. (eds) Future Information Technology. Lecture Notes in Electrical Engineering, vol 309. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55038-6_86
Download citation
DOI: https://doi.org/10.1007/978-3-642-55038-6_86
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-55037-9
Online ISBN: 978-3-642-55038-6
eBook Packages: EngineeringEngineering (R0)